Clinical trials: Hematological Diseases
Red Blood Cells, Schistocytes
ERYthrocyte Morphology Using Flow Imaging on ImageSTREAM Cytometer
Erythrocyte morphology analysis is a key step in the diagnosis flowchart of anemia. It is performed on a peripheral blood smear after May Grümwald Giemsa staining.
- Conditions
- Red Blood Cells, Schistocytes, Artificial Intelligence
- Trial name
- ERYSTREAM (NCT05282888)
- Testing
- blood sample
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Candidiasis, Fungal Infection
PTX3-targeted Antifungal Prophylaxis
This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute…
- Conditions
- Candidiasis, Fungal Infection, Acute Myeloid Leukemia, Genetic Predisposition
- Trial name
- PTX3AML (NCT03828773)
- Testing
- Posaconazole, Fluconazole
- Where
- 9 sites in Belgium, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Bochud Pierre-Yves
Acute Myeloid Leukemia
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
300 patients will be randomly distributed into the control group (n=150) and the experimental group(n=150). Patients will receive two cycles of induction chemotherapy.
- Trial name
- NCT05356169
- Testing
- with or without venetoclax
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia
A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
This was a retrospective, cross-sectional, center-based chart review study that collected real-world data for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients receiving tisagenlecleucel (tisa-cel).
- Trial name
- KareALL (NCT07039383)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p…
- Trial name
- NCT02966756
- Testing
- Venetoclax
- Where
- 31 sites in Australia, China and 2 more
- Volunteers
- 66 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
The main goal of this study is to assess the safety and tolerability of RAD001 in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy.
- Trial name
- NCT00636922
- Testing
- RAD001(Everolimus)
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Bayside Health
T-Cell Acute Lymphoblastic Leukemia
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of T-cell acute lymphoblastic leukemia (T-ALL): multi-antigen-targeted chimeric antigen receptor T cells…
- Trial name
- NCT05277753
- Testing
- Antigen-specific T cells CAR-T/CTL and DCvac
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Sickle Cell Disease, Chronic Pain
Use of a Mobile-based App for SCD Patients
The study will seek to enroll 100 sickle cell or thalassemia patients who are age 12 or older who have access to a smartphone or tablet with Internet access daily.
- Trial name
- SMART (NCT01833702)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
- Trial name
- NCT02492737
- Testing
- AG881
- Where
- 6 sites in United States, France
- Volunteers
- 46 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Breast Cancer, Leukemia
Delayed Effects of Treatment in Cancer Survivors (DETECS)
Hypotheses and Specific Aims: There is limited data on the long-term consequences of cancer therapy on young, reproductively aged cancer survivors.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Gynecologic Cancer
- Trial name
- DETECS (NCT02067637)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Sickle Cell Disease
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
In a hybrid type I effectiveness-implementation trial, our three-center research teams aim to examine whether empowering adults with sickle cell disease (SCD) with patient-facing SCD-specific guidelines through an mHealth…
- Trial name
- PF-Guide (NCT06919224)
- Testing
- mHealth app + booklets
- Where
- 4 sites in United States
- Volunteers
- 287 people
- Sponsor
- Ohio State University
Depression, Hematopoietic and Lymphoid Cell Neoplasm
Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE
This study compares the effectiveness of technology-enhanced collaborative care management (t-CoCM) to usual collaborative care management (u-CoCM) in achieving fidelity to processes of care and reducing depression symptoms in…
- Conditions
- Depression, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05012124
- Testing
- Collaborative care, Interview or Focus Group, Media/technology Intervention with collaborative care
- Where
- 4 sites in United States
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- University of Washington
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00006246
- Testing
- busulfan
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Myelodysplastic Syndrome, Leukemia
Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot
As a result of the underlying disease or its therapy, it is common for patients with blood cancers to have low platelet counts. While platelet transfusions may be beneficial in preventing or treating bleeding symptoms, in…
- Trial name
- OPTIMAL (NCT01615146)
- Testing
- Platelet Transfusion
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- Ottawa Hospital Research Institute
Essential Thrombocythemia
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for…
- Trial name
- SURPASS ET (NCT04285086)
- Testing
- Ropeginterferon alfa-2b, Anagrelide
- Where
- 67 sites in United States, Canada and 6 more
- Volunteers
- 174 people
- Sponsor
- PharmaEssentia
Myeloproliferative Neoplasm, Polycythemia Vera
Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms
Adult patients (>18 years) with newly diagnosis of Ph negative myeloproliferative neoplasms (MPNs) according to WHO 2016 criteria, will be recruited to this study.
- Conditions
- Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis
- Trial name
- NCT06371573
- Testing
- ULTRASOUND EXAM AND MRI SCAN
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Federico II University
Trauma
Rotational Thromboelastometry Activated Transfusion In Trauma Trial
This is a randomized controlled trial to compare viscoelastic (VE) guided resuscitation to fixed-ratio resuscitation in trauma patients with hemorrhagic shock on the utilization of blood products, effects on coagulation and…
- Trial name
- ROTATE-IT (NCT03765866)
- Testing
- Thromboelastometry guided transfusion
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I trial is studying the side effects and the best dose of alvocidib when given together with cyclophosphamide and rituximab in treating patients with high risk B-cell chronic lymphocytic leukemia or small lymphocytic…
- Conditions
- Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT01076556
- Testing
- Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Acute Ischemic Stroke, Cerebral Infarction
Safely Quenching Complement in Stroke Survivors
This study will include adults (ages 18-80) who have had a stroke caused by a large blood clot blocking blood flow in the brain.
- Trial name
- SUCCESS (NCT07495722)
- Testing
- Pegcetacoplan Injection [Empaveli]
- Volunteers
- 20 people
- Sponsor
- Columbia University
Sickle Cell Disease
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab.
- Trial name
- NCT05833022
- Where
- 11 sites in United States
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.